Galmed Pharmaceuticals Ltd.
GLMD
$0.52
-$0.01-1.49%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 16.66% | 10.22% | -13.18% | 3.83% | -16.10% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 51.28% | 35.55% | 4.82% | 12.59% | -10.88% |
| Operating Income | -51.28% | -35.55% | -4.82% | -12.59% | 10.88% |
| Income Before Tax | -51.31% | -37.14% | -37.57% | -48.26% | -15.56% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -51.31% | -37.14% | -37.57% | -48.26% | -15.56% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -51.31% | -37.14% | -37.57% | -48.26% | -15.56% |
| EBIT | -51.28% | -35.55% | -4.82% | -12.59% | 10.88% |
| EBITDA | -18.81% | -36.03% | -5.29% | -13.70% | 11.85% |
| EPS Basic | 68.53% | 70.20% | 84.34% | 78.76% | 81.67% |
| Normalized Basic EPS | 72.69% | 73.68% | 86.70% | 80.25% | 82.54% |
| EPS Diluted | 68.53% | 70.20% | 84.34% | 78.76% | 81.67% |
| Normalized Diluted EPS | 72.69% | 73.68% | 86.70% | 80.25% | 82.54% |
| Average Basic Shares Outstanding | 349.75% | 362.14% | 472.54% | 387.92% | 331.05% |
| Average Diluted Shares Outstanding | 349.75% | 362.14% | 472.54% | 387.92% | 331.05% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |